



Express Mail No.: EV 452 777 051 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Donald J. KYLE et al.

Confirmation No.: 5149

Application No.: 10/607,563

Group Art Unit: 1623

Filed: June 27, 2003

Examiner: Paul V. Ward

Title: THERAPEUTIC AGENTS USEFUL
FOR TREATING PAIN

Attorney Docket No.: 6750-173-999
(CAM No.: 305158-999171)

SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. §§ 1.56 and 1.97

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. §§ 1.56 and 1.97 to inform the Patent and Trademark Office ("Office") of all references coming to the attention of each individual associated with the filing and prosecution of the above-identified application that are or may be related to patentability of the claimed invention, Attorneys for Applicants hereby invite the Examiner's attention to references **A28-A34**, **B12**, **B13** and **C35-C41** which are listed on the accompanying Substitute for Form PTO-1449 entitled "Information Disclosure Statement By Applicant." This Supplemental Information Disclosure Statement supplements the Information Disclosure Statement filed on November 1, 2005.

Legible copies of references **B12**, **B13** and **C35-C41** are submitted herewith. Pursuant to 37 C.F.R. § 1.98(a)(2)(ii), copies of references **A28-A34**, being United States Patents and Patent Application Publications, are not submitted herewith but will be submitted if requested by the Office.

No admission is made that the information cited in this Supplemental Information Disclosure Statement is, or is considered to be, material to patentability and no representation is made that a search has been made. 37 C.F.R. §§ 1.97(g) and (h).

Applicants request that the Examiner review all the references identified on the attached Substitute for Form PTO-1449, and that they be made of record in the file history of the above-identified application.

As this Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits, Applicants estimate that no fee is required. Should a fee be required, the Commissioner is authorized to charge the required fee to Jones Day Deposit Account No. 50-3013.

Respectfully submitted,

Date: March 22, 2006

*Samuel B. Abrams by
George A. Smith 42,140*

Samuel B. Abrams

(Reg. No. 30,605)

JONES DAY

222 East 41st Street

New York, New York 10017

(212) 326-3939

Enclosures



Substitute for Form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use several sheets if necessary)ATTY DOCKET NO.
6750-173-999
(CAM No. 305158-999171)APPLICATION NO.
10/607,563APPLICANT:
Donald J. KYLE et al.FILING DATE:
June 27, 2003

ART UNIT: 1623 CONF. NO.: 5149

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS*	Cite No.	DOCUMENT NUMBER	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A28	6,020,349	02/01/2000	Ankersen et al.	
	A29	6,083,960	07/04/2000	Ankersen et al.	
	A30	2004/0019099 A1	01/29/2004	Aslanian et al.	
	A31	2004/0048843 A1	03/11/2004	Ting et al.	
	A32	2004/0097483 A1	05/20/2004	Zeng et al.	
	A33	2004/0204397 A1	10/14/2004	Chaturvedula et al.	
	A34	2006/0004053 A1	01/05/2006	Arnould	
	A35				

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS*	Cite No.	Country Code, Number, Kind of Code (if known)	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
						YES	NO
	B12	WO 02/18335 A1	03/07/2002	Yamanouchi Pharmaceutical Co., Ltd. and Toray Industries Inc.		XXX	
	B13	WO 2004/064721 A2	08/05/2004	Tanabe Seiyaku Co., Ltd.			
	B14						

NON PATENT LITERATURE DOCUMENTS

EXAMINER'S INITIALS*	Cite No.	<i>Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume, publisher, city and/or country where published., etc.</i>
	C35	WRIGGLESWORTH et al., "Capsaicin-like Agonists," <i>Drugs of the Future</i> 23(5):531-538 (1998)
	C36	SZALLASI et al., "Vanilloid (Capsaicin) Receptors and Mechanisms," <i>Pharmacol. Revs.</i> 51(2):159-211 (1999)
	C37	SZALLASI et al., "The Cloned Rat Vanilloid Receptor VR1 Mediates Both R-Type Binding and C-Type Calcium Response in Dorsal Root Ganglion Neurons," <i>Molec. Pharmacol.</i> 56:581-587 (1999)
	C38	BEVAN et al., "Vanilloid Receptors: Pivotal Molecules in Nociception," <i>Current Opinions in CPNS Investigational Drugs</i> 2(2):178-185 (2000)
	C39	WANG et al., "High Affinity Antagonists of the Vanilloid Receptor," <i>Mol. Pharmacol.</i> 62(4):947-956 (2002)
	C40	LOPEZ-RODRIGUEZ et al., "VR1 Receptor Modulators as Potential Drugs for Neuropathic Pain," <i>Mini-Revs in Medicinal Chem.</i> 3(7):729-748 (2003)
	C41	POMONIS et al., "N-(4-Tertiarybutylphenyl)-4-(3-chlorophyridin-2-yl)tetrahydropyrazine-1(2H)-carbox-amide (BCTC), a Novel, Orally Effective Vanilloid Receptor 1 Antagonist with Analgesic Properties: II. In Vivo Characterization in Rat Models of Inflammatory and Neuropathic Pain," <i>J. Pharmacol. Exper. Therapeutics</i> 306(1):387-393 (2003)
	C42	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.